Results of a Multicenter Open-Label Randomized Trial Evaluating Infusion Duration of Zoledronic Acid in Multiple Myeloma Patients (the ZMAX Trial)

Journal of Supportive Oncology

Volumn 9, Issue 1, 2011, Pages 32-40

  Berenson, James R ^a,b,c,d,e   Boccia, Ralph ^a,b,c,d,e   Lopez, Timothy ^a,b,c,d,e   Warsi, Ghulam M ^a,b,c,d,e   Argonza Aviles, Eliza ^a,b,c,d,e   Lake, Simone ^a,b,c,d,e   Ericson, Solveig G ^a,b,c,d,e   Collins, Robert ^a,b,c,d,e  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^b Center for Cancer and Blood Disorders   (United States)

^c New Mexico Cancer Care Associates   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE ATROPHY; BONE PAIN; BRADYCARDIA; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE KIDNEY FUNCTION RELATION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; HEART ARRHYTHMIA; HUMAN; HYPOKALEMIA; INFUSION RATE; INSOMNIA; JAW OSTEONECROSIS; JAW PAIN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; OPEN STUDY; PAIN; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT DISEASE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 79955974622     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suponc.2010.12.002     Document Type: Article

References (15)

1. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Kyle R.A., Gertz M.A., Witzig T.E., et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003, 78(1):21-33.
3. Corso A., Zappasodi P., Pascutto C., et al. Urinary proteins in multiple myeloma: correlation with clinical parameters and diagnostic implications. Ann Hematol 2003, 82(8):487-491.
4. Eleutherakis-Papaiakovou V., Bamias A., Gika D., et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 2007, 48(2):337-341.
5. Rosen L.S., Gordon D., Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001, 7(5):377-387.
6. Rosen L.S., Gordon D., Kaminski M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98(8):1735-1744.
7. Zometa (package insert) 2008, Novartis Pharmaceuticals, Corporation, East Hanover, NJ.
8. Major P., Lortholary A., Han J., et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001, 19(2):558-567.
9. Chen T., Berenson J., Vescio R., et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002, 42(11):1228-1236.
10. Pfister T., Atzpodien E., Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 2003, 191:159-167.
11. Pfister T., Aztpodien E., Bohrmann B., Bauss F. Acute renal effects of intravenous bisphosphonates in the rat. Basic Clin Pharmacol Toxicol 2005, 97:374-381.
12. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94(19):1458-1468.
13. Kautiainen S., Luurila S., Ylitalo P., Ylitalo R. Transformation of bisphosphonates into insoluble material in human blood in vitro. Methods Find Exp Clin Pharmacol 1998, 20(4):289-295.
14. Rosen L.S., Gordon D., Tchekmedyian S., et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003, 21(16):3150-3157.
15. Hussein M.A. Multiple myeloma: most common end-organ damage and management. J Natl Compr Canc Netw 2007, 5(2):170-178.